Abstract:Background and Objective: Phosphatidylinositol 3-kinase (PI3K) is the central regulator of cellular functions and is suggested as a target for various diseases, thus, effective PI3K inhibitors provide a promising opportunity for the pharmaceutical intervention of many diseases. Among them, PI3Kγ has to be paid more attention because of its essential in immune signaling. However, the development of novel selective PI3Kγ inhibitors is a big challenge due to the high sequence homology across the class I PI3K isoforms. Therefore, understanding in the substrate specificity and receptor-ligand interaction of PI3Kγ would be an appropriate strategy to rational design potent γ-selective inhibitors.Methods: In this study, by combining various molecular modeling approaches (including classical and enhanced sampling molecular dynamics (MD) simulations, end-point binding free energy calculations, and pharmacophore models), three quinolinone-core containing inhibitors, Idelalisib/CAL-101, Duvelisib/IPI-145, and Eganelisib/IPI-549, were employed to reveal the selective binding mechanisms targeting PI3Kγ.Results: The classical MD and free energy calculations highlight the significant interaction and some key residues for the selective binding against PI3Kγ. Furthermore, the dissociation pathway analysis based on umbrella sampling simulations reveals that hydrophobic interactions are dominant for binding of the three ligands during the dissociation processes, and cooperation between the P-loop and the ligands always exist in the binding/dissociation process. Last, the pharmacophore model reveals that IPI-549 contains a unique hydrophobic feature, and the PI3Kγ exhibit an important hydrogen bond donor feature of hydrogen amide.Conclusions: These findings may provide some important information for rational designing and optimizing of PI3Kγ selective inhibitor.

Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

A Selectivity Study On Mtor/Pi3k Alpha Inhibitors By Homology Modeling And 3d-Qsar

A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

A Systematic Molecular and Pharmacologic Evaluation of AKT Inhibitors Reveals New Insight into Their Biological Activity

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Targeting mTOR Kinase with Natural Compounds: Potent ATP-Competitive Inhibition Through Enhanced Binding Mechanisms

Phospshoinositide 3-Kinase (pi3k)/mammalian Target of Rapamycin (mtor) Dual Inhibitors: Discovery and Structure-Activity Relationships of A Series of Quinoline and Quinoxaline Derivatives

ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding

The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization

Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies

3D-QSAR and Surflex-dock Study of Pyrimidine Scaffold Compounds As Dual PI3K/mTOR Inhibitors

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in Mtor Kinase

Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance

Exploring Binding Preference of Three Drugs Targeting Pi3Kγ Via Energetic, Pharmacophore and Dissociation Pathway Analyses

Investigation of Selective Binding of Inhibitors to PTP1B and TCPTP by Accelerated Molecular Dynamics Simulations.